▟ Vinebot intrinsic value, daily

← back

EW Edwards Lifesciences

healthcare · valued with opus medium conviction · deep-dived 2026-10-26

HOLD
Intrinsic value$43.77
Price (at call)$89.07
Margin of safety -50.9%
vs market (rating basis) -14.3%

Structural heart franchise with TAVR moat and mitral/tricuspid runway; margins recover from charge-depressed trough.

The story

Edwards is the global leader in transcatheter aortic valve replacement (TAVR) and is building a second growth engine in mitral and tricuspid therapies (PASCAL, EVOQUE, SAPIEN M3). Its moat comes from clinical-evidence leadership, deep relationships with heart teams and regulatory barriers. Since selling Critical Care it is a pure-play structural heart franchise in late high growth. TAVR is maturing toward high-single-digit growth, while asymptomatic aortic stenosis indications and TMTT extend the reinvestment runway.

Growth of about 9% reflects TAVR at high single digits plus TMTT growing faster, below the roughly 11% 5-year CAGR as the core matures. The reported 21% margin is depressed by litigation, acquisition and separation charges, so margins recover to about 28%, below the 34% peak because of TMTT investment and pricing pressure. Incremental sales-to-capital of 1.3 replaces the trailing 0.58, which is distorted by excess cash and acquired goodwill. A 10-year horizon fits a durable but not unassailable franchise.

Value drivers

Revenue growth (Y1)9.0%
Terminal growth3.5%
Forecast horizon10y
Target operating margin28.0%
Years to target margin4
Sales-to-capital1.30
Beta0.95
Failure probability1.0%
Cost of capital (WACC)9.2%
Terminal WACC9.4%

Valuation bridge

PV of explicit FCFF10.16B
PV of terminal value12.96B
Equity value25.20B
÷ shares → per share$43.77

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 6.87B 9.0% 23.6% 1.35B 436.40M 910.80M 833.92M
2 7.45B 8.4% 25.1% 1.55B 443.37M 1.11B 927.79M
3 8.03B 7.8% 26.5% 1.77B 445.56M 1.32B 1.01B
4 8.60B 7.2% 28.0% 2.00B 442.48M 1.56B 1.09B
5 9.17B 6.6% 28.0% 2.13B 433.76M 1.70B 1.09B
6 9.71B 5.9% 28.0% 2.26B 419.11M 1.84B 1.08B
7 10.23B 5.3% 28.0% 2.38B 398.37M 1.98B 1.07B
8 10.71B 4.7% 28.0% 2.49B 371.54M 2.12B 1.05B
9 11.15B 4.1% 28.0% 2.59B 338.73M 2.25B 1.02B
10 11.54B 3.5% 28.0% 2.68B 300.24M 2.38B 985.77M

Key risks

  • TAVR share loss to Medtronic, Abbott and Boston Scientific, plus hospital capacity limits on procedure growth
  • TMTT adoption or reimbursement slower than expected, leaving margins diluted by R&D and commercial spend
  • Clinical or safety setbacks, product liability and patent litigation, and FTC scrutiny of acquisitions such as JenaValve

Catalysts

  • Label expansion and guideline updates for asymptomatic severe aortic stenosis (EARLY TAVR) driving procedure growth
  • EVOQUE and SAPIEN M3 scaling with positive data and CMS coverage, lifting TMTT toward $1B+

History

DatePriceIntrinsicMoSRating
2026-10-26$89.07 $43.77 -50.9% HOLD
2026-09-04$89.78 $22.59 -74.8% SELL
2026-07-15$90.09 $38.24 -57.6% HOLD
2026-06-23$86.95 $39.13 -55.0% HOLD